CF Therapies - Clinical Trials Program
The CF Genetic Modifier Project (supported by Genome Canada, CCFF and NIH)
Investigators: Peter Durie and Julian Zielenski.
We have established the largest resource of clinical and genetic data, on 80 per cent of Canadian CF patients, in the world. We are using this resource at our Centre to look for gene modifiers (factors that can influence severity of disease that may also serve as potential therapeutic targets), and we have also established a modifier gene consortium for other investigators to access this resource. This involves collaborations with people in at least 12 countries, including two Canadian and one U.S. scientific sites as well as 32 Canadian CF clinics.
The Cystic Fibrosis Mutation Database (CFTR1)
Initiated by Dr. Lap-Chee Tsui and the Cystic Fibrosis Genetic Analysis Consortium in 1989 to increase and facilitate communications among CF researchers, the CFTR1 project aims to provide up to date information about individual mutations in the CFTR gene. There is an online process for the submission of new mutations and follow up analysis to ensure consistent, complete information without duplication. As part of a major 2010 upgrade, CFTR1 connects to a new project called CFTR2 - The Clinical and Functional TRanslation of CFTR, based at The Johns Hopkins University, which links clinical information from patient registries around the world to specific CFTR mutations. Together CFTR1 and CFTR2 investigators will lead and support world-class research on genotype-phenotype correlation.